TY - JOUR
T1 - Associations of Angiotensin Converting Enzyme-1 and Angiotensin II Blood Levels and Cognitive Function
AU - Yasar, Sevil
AU - Varma, Vijay R.
AU - Harris, Gregory C.
AU - Carlson, Michelle C.
N1 - Funding Information:
We thank the Brain Health Substudy (BHS) study participants for their critical contributions to this research along with funding from the Johns Hopkins Neurobehavioral Research Unit, a supplement to the NIH grant #P01AG027735-03 and the Alzheimer’s Drug Discovery Foundation.
Funding Information:
We acknowledge the support of the Johns Hopkins University Institute for Clinical and Translational Research Clinical Research Core Laboratory for the performance of ACE and ANGII measures. The project described was supported in part by the National Center for Advancing Translational Sciences, NIH #UL1TR001079 and #R37AG19905 grants.
Funding Information:
S. Yasar has received research support for this study from the John Johns Hopkins University Pepper Center NIA #P30AG021334 and the Nathan Shock Memorial Fund. V. Varma is supported by the Intramural Research Program, National Institute on Aging, NIH. G. Harris and M. Carlson report no funding.
Publisher Copyright:
© 2018 - IOS Press and the authors. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Background: Emerging evidence suggests a possible role of the renin angiotensin system in the pathophysiologic process of Alzheimer's disease, of which angiotensin converting enzyme-1 (ACE-1) and angiotensin II (ANGII) are important proteins. Few studies evaluated associations between blood ACE-1 and none between ANGII levels, and cognition. Objective: Our pilot study was aimed to examine associations between blood ACE-1 and ANG II levels and cognitive function in non-demented participants at baseline and over a 1-year period. Methods: 56 participants were included from the Brain Health Substudy of the Baltimore Experience Corps Study. Linear regression analysis, adjusting for confounders, was used to determine associations between baseline ACE-1 and ANGII, and baseline and 1-year follow-up measures of psychomotor and processing speed, executive function, verbal learning memory and working memory, and whether these associations were mediated by blood pressure. Results: Participants were predominantly female (75%), African-American (93%), with mean age of 67.8 years and education of 14.3 years. There were no associations between baseline ACE-1 or ANGII levels and cognitive function; however, there were significant association between baseline ACE-1 levels and 1-year follow-up Trail Making Test, Part A (β=0.003, p=0.04) and Digit Span (β=-0.001, p=0.02). Conclusions: In this cognitively intact sample, elevated ACE-1 levels were associated with worse processing speed and working memory after 1 year. Findings from this pilot study suggest that changes in the RAS are associated with alterations in cognitive function warranting further assessment of the role of RAS in neurodegenerative disorders.
AB - Background: Emerging evidence suggests a possible role of the renin angiotensin system in the pathophysiologic process of Alzheimer's disease, of which angiotensin converting enzyme-1 (ACE-1) and angiotensin II (ANGII) are important proteins. Few studies evaluated associations between blood ACE-1 and none between ANGII levels, and cognition. Objective: Our pilot study was aimed to examine associations between blood ACE-1 and ANG II levels and cognitive function in non-demented participants at baseline and over a 1-year period. Methods: 56 participants were included from the Brain Health Substudy of the Baltimore Experience Corps Study. Linear regression analysis, adjusting for confounders, was used to determine associations between baseline ACE-1 and ANGII, and baseline and 1-year follow-up measures of psychomotor and processing speed, executive function, verbal learning memory and working memory, and whether these associations were mediated by blood pressure. Results: Participants were predominantly female (75%), African-American (93%), with mean age of 67.8 years and education of 14.3 years. There were no associations between baseline ACE-1 or ANGII levels and cognitive function; however, there were significant association between baseline ACE-1 levels and 1-year follow-up Trail Making Test, Part A (β=0.003, p=0.04) and Digit Span (β=-0.001, p=0.02). Conclusions: In this cognitively intact sample, elevated ACE-1 levels were associated with worse processing speed and working memory after 1 year. Findings from this pilot study suggest that changes in the RAS are associated with alterations in cognitive function warranting further assessment of the role of RAS in neurodegenerative disorders.
KW - Angiotensin II
KW - angiotensin converting enzyme-1
KW - cognition
KW - cohort study
UR - http://www.scopus.com/inward/record.url?scp=85048376706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048376706&partnerID=8YFLogxK
U2 - 10.3233/JAD-170944
DO - 10.3233/JAD-170944
M3 - Article
C2 - 29660936
AN - SCOPUS:85048376706
SN - 1387-2877
VL - 63
SP - 655
EP - 664
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 2
ER -